PE129799A1 - Inhibidores de benzotiazol de la proteina tirosina cinasa - Google Patents

Inhibidores de benzotiazol de la proteina tirosina cinasa

Info

Publication number
PE129799A1
PE129799A1 PE1998001078A PE00107898A PE129799A1 PE 129799 A1 PE129799 A1 PE 129799A1 PE 1998001078 A PE1998001078 A PE 1998001078A PE 00107898 A PE00107898 A PE 00107898A PE 129799 A1 PE129799 A1 PE 129799A1
Authority
PE
Peru
Prior art keywords
alkylene
alkynyl
link
benzotiazole
inhibitors
Prior art date
Application number
PE1998001078A
Other languages
English (en)
Inventor
Jagabandhu Das
John Wityak
Joel C Barrish
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE129799A1 publication Critical patent/PE129799A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN BENZOTIAZOL DE FORMULA I; p ES 0-3; X1 Y X2 SON H o JUNTOS FORMAN =O o =S; R1 ES H, R6, OH, OR6, SH, C(O)qH, SO3H, -Z4-NR7R8, -Z4-N(R9)-Z5-NR10R11, ENTRE OTROS; q ES 1 o 2; R6 ES ALQUILO, ALQUENILO, ALQUINILO, OPCIONALMENTE SUSTITUIDO CON Z1, Z2, Z3, ENTRE OTROS; R2 Y R3 SON H, R6, -Z4-R6, -Z13NR7R8; R4 Y R5 SON H, R6 o JUNTO CON N FORMAN UN ANILLO HETEROCICLICO DE 3-8 MIEMBROS OPCIONALMENTE SUSTITUIDO CON Z1, Z2, Z3; R7, R8, R9, R10 Y R11 SON H, R6; o JUNTOS R7 Y R8 o DOS DE R9, R10 Y R11 SON ALQUILENO, ALQUENILENO, ANILLO DE 3-8 MIEMBROS, ENTRE OTROS; Z1, Z2, Z3 SON H, Z6, OH, SH, C(O)qH, SO3H, HALO, CIANO, ENTRE OTROS; Z6 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS; Z4 Y Z5 SON UN ENLACE, -Z11-S(O)q-Z12-, -Z11-C(S)-Z12-, ENTRE OTROS, Z11 Y Z12 SON ENLACE, ALQUILENO, ALQUENILENO, ALQUINILENO; Z13 ES ENLACE, -Z11-S(O)q-Z12-, -Z11-C(O)-Z12-, ENTRE OTROS. UN COMPUESTO PREFERIDO ES ACIDO [6-[[[2,4,6-TRIMETILFENIL)AMINO]CARBONIL]-2-BENZOTIAZOLIL]CARBAMICO, ESTER DE 1,1-DIMETILETILO, ENTRE OTROS. EL COMPUESTO I ES UN INHIBIDOR DE LA ENZIMA TIROSINA CINASA Y PUEDE SER UTIL EN CASO DE RECHAZO DE TRANSPLANTE, O EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, INFLAMACION DEL INTESTINO, LUPUS, HIPERSENSIBILIDAD MEDIADA POR LA CELULA T, PSORIASIS, TIROIDITIS DE HASHIMOTO
PE1998001078A 1997-11-10 1998-11-10 Inhibidores de benzotiazol de la proteina tirosina cinasa PE129799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6504297P 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
PE129799A1 true PE129799A1 (es) 2000-03-08

Family

ID=22059964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001078A PE129799A1 (es) 1997-11-10 1998-11-10 Inhibidores de benzotiazol de la proteina tirosina cinasa

Country Status (25)

Country Link
US (1) US6825355B2 (es)
EP (1) EP1037632B1 (es)
JP (1) JP2001522800A (es)
KR (1) KR20010031912A (es)
CN (1) CN1290165A (es)
AR (1) AR017588A1 (es)
AT (1) ATE315394T1 (es)
AU (1) AU744281B2 (es)
BR (1) BR9814956A (es)
CA (1) CA2309319A1 (es)
DE (1) DE69833224T2 (es)
ES (1) ES2256969T3 (es)
HU (1) HUP0102101A3 (es)
ID (1) ID24289A (es)
IL (1) IL135176A0 (es)
NO (1) NO20002121L (es)
NZ (1) NZ503491A (es)
PE (1) PE129799A1 (es)
PL (1) PL340727A1 (es)
RU (1) RU2212407C2 (es)
TR (1) TR200001312T2 (es)
TW (1) TW510898B (es)
UY (1) UY25242A1 (es)
WO (1) WO1999024035A1 (es)
ZA (1) ZA9810219B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258686A1 (en) * 1998-05-29 2006-11-16 Cheresh David A Method of treatment of myocardial infarction
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
JP5036112B2 (ja) * 1999-10-06 2012-09-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有益な複素環化合物
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
CA2417635C (en) * 2000-08-11 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2003041708A1 (en) 2001-11-09 2003-05-22 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazoles useful as protein kinase inhibitors
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
JP2006502133A (ja) * 2002-08-10 2006-01-19 アステックス、セラピューティックス、リミテッド サイクリン依存キナーゼ（ｃｄｋ）インヒビターとしての３−（カルボニル）１ｈ−インダゾール化合物
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
EP1608639A2 (en) * 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP2006521345A (ja) * 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
PL1636585T3 (pl) 2003-05-20 2008-10-31 Bayer Healthcare Llc Diarylowe pochodne mocznika inhibowane kinazą
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
MXPA06007667A (es) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
AU2005210474B2 (en) * 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP4996926B2 (ja) * 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
DE102004006808A1 (de) * 2004-02-11 2005-09-01 Grünenthal GmbH Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
BRPI0511543B1 (pt) 2004-05-24 2022-05-10 F. Hoffmann-La Roche Ag. Ácido 4-hidróxi-4-metila-piperidina-1-carboxílico (4-metóxi-7-morfolin-4-il-benzotiazol-2-il)- amida, seu processo de preparação, uso e medicamento que o compreende
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
ES2309814T3 (es) 2004-11-05 2008-12-16 F. Hoffmann-La Roche Ag Proceso para la obtencion de derivados del acido isonicotinico.
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
EP1954696B1 (en) * 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
CA2600570C (en) * 2005-03-14 2011-12-06 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
EP1863818B1 (en) 2005-03-23 2010-03-10 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ES2352796T3 (es) * 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
EP1896466B1 (en) * 2005-06-27 2011-04-13 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007006761A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008109459A1 (en) * 2007-03-02 2008-09-12 University Of Massachusetts Luciferins
JP2008222084A (ja) * 2007-03-14 2008-09-25 Yamaha Motor Electronics Co Ltd 電動ゴルフカーのブレーキ劣化検出方法及びこれを用いた電動ゴルフカー
WO2008124393A1 (en) * 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors
FR2928547B1 (fr) 2008-03-13 2012-03-09 Lvmh Rech Extrait de l'orchidee brassocattle marcella koss et son utilisation en tant qu'actif de depigmentation cutanee
ES2547124T3 (es) * 2009-04-02 2015-10-01 Merck Patent Gmbh Inhibidores de autotaxina
WO2010126743A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS
CN101701018B (zh) * 2009-11-05 2012-06-13 东南大学 2-(4-氨基喹唑啉基)苯并[d]噻唑类衍生物及其用途
CA2792339A1 (en) * 2010-03-23 2011-09-29 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
CN108864151A (zh) 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
MX368081B (es) * 2011-10-14 2019-09-19 Ambit Biosciences Corp Compuestos heterociclicos y uso de los mismos como moduladores del receptor de tirosina cinasas tipo iii.
US9540364B2 (en) * 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
CN103058954A (zh) * 2013-01-07 2013-04-24 盛世泰科生物医药技术(苏州)有限公司 一种[6-(5-氨基-2-甲基-苯氨基甲酰-苯并噻唑]-氨基甲酸叔丁酯的制备方法
EP2991967A1 (en) * 2013-03-20 2016-03-09 F. Hoffmann-La Roche AG Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014168262A1 (en) * 2013-04-11 2014-10-16 D.D.P. Corporation Kinase inhibitors containing cyclopropane skeleton
EP2990027A1 (en) 2014-09-01 2016-03-02 Institut Curie Skin whitening peptide agents
AU2015337607B2 (en) * 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
CA2989098A1 (en) 2015-06-22 2016-12-29 Actelion Pharmaceuticals Ltd Nadph oxidase 4 inhibitors
KR102089122B1 (ko) 2016-08-25 2020-03-13 주식회사 엘지화학 디아민 화합물 및 이를 이용하여 제조된 플렉시블 소자용 기판
CN107021937B (zh) * 2017-03-27 2019-06-21 沈阳药科大学 苯并噻唑甲酰胺类化合物及其应用
CN108794487B (zh) * 2017-05-04 2020-11-10 上海长森药业有限公司 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
CA3067070A1 (en) * 2017-06-14 2018-12-20 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
EP3692023B1 (en) * 2017-10-02 2023-05-17 1st Biotherapeutics, Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CN115594671B (zh) * 2021-07-08 2024-03-15 沈阳药科大学 苯并噻唑类衍生物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966706A (en) * 1971-01-27 1976-06-29 Ciba-Geigy Ag 2,6-Dihydroxy-3-cyano-4-methylpyridine containing azo dyes which contain a functional amino group
JPS50140442A (es) * 1974-04-16 1975-11-11
JPS5632549A (en) * 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
JPS62194251A (ja) * 1986-02-20 1987-08-26 Konishiroku Photo Ind Co Ltd 保存安定性が改良されたハロゲン化銀写真感光材料
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
US4970318A (en) * 1988-05-24 1990-11-13 Pfizer Inc. Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) * 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
JP2869561B2 (ja) 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
CA2118425C (en) * 1993-02-19 1997-08-12 Akiro Kajihara Benzothiazolesulfonamide derivative, method for preparing the same, and use thereof
US5496816A (en) 1994-03-14 1996-03-05 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
EP0944645B1 (en) 1996-12-06 2005-03-09 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ES2308821T3 (es) 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.

Also Published As

Publication number Publication date
KR20010031912A (ko) 2001-04-16
TR200001312T2 (tr) 2000-09-21
AU744281B2 (en) 2002-02-21
AU1371999A (en) 1999-05-31
DE69833224T2 (de) 2006-09-28
RU2212407C2 (ru) 2003-09-20
US6825355B2 (en) 2004-11-30
WO1999024035A1 (en) 1999-05-20
ZA9810219B (en) 2000-06-22
US20020123484A1 (en) 2002-09-05
UY25242A1 (es) 2001-08-27
JP2001522800A (ja) 2001-11-20
ID24289A (id) 2000-07-13
HUP0102101A3 (en) 2002-11-28
HUP0102101A2 (hu) 2001-11-28
NO20002121L (no) 2000-05-09
NO20002121D0 (no) 2000-04-26
CA2309319A1 (en) 1999-05-20
AR017588A1 (es) 2001-09-12
NZ503491A (en) 2002-08-28
BR9814956A (pt) 2000-10-03
DE69833224D1 (en) 2006-04-06
TW510898B (en) 2002-11-21
EP1037632A4 (en) 2002-08-21
ES2256969T3 (es) 2006-07-16
EP1037632A1 (en) 2000-09-27
ATE315394T1 (de) 2006-02-15
EP1037632B1 (en) 2006-01-11
CN1290165A (zh) 2001-04-04
IL135176A0 (en) 2001-05-20
PL340727A1 (en) 2001-02-26

Similar Documents

Publication Publication Date Title
PE129799A1 (es) Inhibidores de benzotiazol de la proteina tirosina cinasa
PE106300A1 (es) Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa
ES2118254T3 (es) Sales de amonio polimericas reticuladas.
ES2123065T3 (es) Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
MX9101957A (es) Carbamatos de aminosulfonilo
DE69132435T2 (de) Inhibitoren retroviraler Proteasen
DK97890D0 (da) Fremgangsmaade til fremstilling af mevalolactonanaloge
CA2158268A1 (en) N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TR199701355A2 (xx) L�kozit adhasyonu inhibit�rleri olarak yeni heterosiklenler ve vla-4-antagonistleri.
ATE325607T1 (de) Aptoptoseinhibitoren
GB9308957D0 (en) Novel produgs
EP0031567A3 (en) Tetrapeptidesemicarbazide derivatives and their production and use
ES2059301T3 (es) Utilizacion de inhibidores de la enzima convertidora de angiotensina para el tratamiento de la aterosclerosis, trombosis y de la enfermedad vascular periferica.
ES2160696T3 (es) Sales de amonio polimeras reticuladas.
DE69513837T2 (de) Cyklopeptolide
ATE228520T1 (de) Lactamverbindungen als inhibitoren der cholesterin-esterase
DE69328408D1 (de) Herstellung von Borester
ES480384A1 (es) Procedimiento de produccion de nuevas neplanocinas antibioticas.
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ES8203363A1 (es) Un procedimiento para la preparacion de 1-oxo-1h-tiazolo-( 3-2-a) pirimidina.
DE69512893D1 (de) Verschleissschutzadditive und ihre verwendung
ES8604691A1 (es) Perfeccionamientos en los metodos para determinar la actividad de la catepsina b en presencia de otras enzimas proteoliticas
EP0177897A3 (en) Antibacterial 7beta-heterocyclic-cephem
ES8507105A1 (es) Un procedimiento para la preparacion de n-(tio-1-oxopropil)-n-(4-fenilciclohexil)-glicinas.
MX9706609A (es) Procedimiento para la obtencion de aminas opticamente activas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed